Kura Oncology Inc. has entered into a collaboration agreement with Kyowa Kirin to develop ziftomenib, an investigational oral menin inhibitor for acute myeloid leukemia (AML). As part of this partnership, Kura has received milestone payments totaling $105 million, including a recent $30 million payment triggered by the start of the second Phase 3 KOMET-017 clinical trial. The collaboration allows for additional near-term milestone payments of up to $315 million as the program advances. The KOMET-017 trials are evaluating ziftomenib in combination with both intensive and non-intensive chemotherapy regimens for patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567577-en) on November 03, 2025, and is solely responsible for the information contained therein.